buyNotable cluster of 3
Chimovits Erez bought $14M of UPB
director, owner at Upstream Bio, Inc.. 825,000 shares at an average of $17.00, traded Oct 15, 2024, filed Oct 17, 2024.
Conviction score
65Value
$14M
825,000 shares
Holdings after
4,554,873
+85% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +7.9%, 3m -53.9%, 6m -62.8%.
Price, last year
Rows in this filing
Every transaction in Form 4 0000947871-24-000807, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | CConversion Common Stockindirect: See Footnote | +721,956 | - | - | 973,716 | Oct 17, 2024 |
| Oct 15, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +165,000 | $17.00 | $2.8M | 1,138,716 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Common Stockindirect: See Footnote | +2,887,833 | - | - | 3,894,873 | Oct 17, 2024 |
| Oct 15, 2024 | POpen-market purchase Common Stockindirect: See Footnote | +660,000 | $17.00 | $11M | 4,554,873 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Series A redeemable convertible preferred stockderivativeindirect: See Footnote | -524,500 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Series A redeemable convertible preferred stockderivativeindirect: See Footnote | -2,098,000 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Series B redeemable convertible preferred stockderivativeindirect: See Footnote | -197,456 | - | - | 0 | Oct 17, 2024 |
| Oct 15, 2024 | CConversion Series B redeemable convertible preferred stockderivativeindirect: See Footnote | -789,833 | - | - | 0 | Oct 17, 2024 |
Related signals
Other insiders at Upstream Bio, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 40Moderate | buy 310b5-1 | UPB Upstream Bio, Inc. | AI Upstream LLC owner | $20M | 1,175,000 | |
| 65Notable | buy 3 | UPB Upstream Bio, Inc. | ORBIMED ADVISORS LLC director, owner | $14M | 825,000 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.